Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

M-Clopidogrel · DIN 02502283 Manufacturer: Mantra Pharma Inc.; listing date 2021-11-30 Health Canada: Marketed since 2020-11-03 · brand M-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Mantra pharma inc · schedule Prescription

DIN 02502283: M-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id MAT Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02502283 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99186

Interchangeable products

Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631

Shortage status: resolved shortage (ended 2026-02-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02502283

Shortage record checked 2026-09-13T08:10:21.292534+00:00